You are here: Industry Insights > novo

News List

Novo data buttress its oral semaglutide case, this time in kidney-impaired patients fiercepharma
August 21, 2018
The approval case for Novo Nordisk’s oral GLP-1 diabetes candidate keeps on building, this time with new data in patients with kidney troubles.
Novo buys Ziylo for glucose-responsive insulin platform fiercebiotech
August 20, 2018
Novo Nordisk has bought Ziylo to fuel its work on next-generation insulins. The takeover gives Novo control of a platform that could support development of insulins that respond to glucose.
Novo has a big pricing decision to make with semaglutide. Which way will it go? fiercepharma
August 14, 2018
As Novo Nordisk’s highly anticipated semaglutide pill nears the market, the company has a big decision to make: at what price?
Novo CEO: Expect U.S. diabetes drug prices to continue their downward spiral next year fiercepharma
August 09, 2018
Price-pressured Novo Nordisk expects basal insulin prices to sink even further next year—but that shouldn’t surprise investors too much, the company’s CEO says.
Novo's oral semaglutide beats Victoza and Januvia in diabetes pharmafile
June 22, 2018
Novo Nordisk has released new data for its oral semaglutide diabetes therapy from two trials, showing that the GLP-1 analogue was more effective in reducing HbA1c and weight in patients compared to MSD’s Januvia (sitagliptin) and its own best-selling inje
Kallyope and Novo Nordisk announce obesity and diabetes collaboration pharmafile
June 22, 2018
Kallyope and Novo Nordisk have entered into a research collaboration and option agreement to discover novel peptide therapeutics for the treatment of obesity and diabetes.
Novo, Kallyope link to develop obesity, diabetes therapies pharmatimes
June 21, 2018
Novo Nordisk and Kallyope are joining forces to discover novel peptide therapeutics for obesity and diabetes.
Novo’s oral semaglutide beats Lilly/Boehringer’s Jardiance pharmatimes
June 06, 2018
Novo Nordisk has announced headline data from the PIONEER 2 trial showing that oral semaglutide was better at improving HbA1c levels in patients with type II diabetes than Lilly’s and Boehringer Ingelheim's Jardiance.
Novo Nordisk’s oral diabetes drug beats Jardiance in study financialexpress
June 01, 2018
Novo Nordisk has announced that data from a large final-stage study of a pill. The company hopes it will transform the diabetes market proved better at lowering blood sugar levels than Eli Lilly and Boehringer Ingelheim’s established Jardiance.
Novo Nordisk's oral GLP-1 analogue Ozempic bests Eli Lilly, Boehringer Ingelheim's Jardiance in late-stage trial firstwordpharma
May 30, 2018
Novo Nordisk announced headline results Tuesday from the Phase IIIa PIONEER 2 trial showing that a once-daily oral formulation of its GLP-1 analogue Ozempic (semaglutide) led to superior improvement in HbA1c levels in adults with type 2 diabetes

Previous page 1 2 3 4 Next page